Hot Results
- Quick Search
- Large-scale studies
- Genome-wide Association Studies of ADHD
- Genome-wide Linkage Studies of ADHD
- Genome-wide CNV Analyses of ADHD
- Meta-analysis Studies of ADHD
- Data Summary
KEGG Pathway Report
Basic Info
| ID | hsa05223 |
|---|---|
| Name | Non-small cell lung cancer |
| Description | Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer and represents a heterogeneous group of cancers, consisting mainly of squamous cell (SCC), adeno (AC) and large-cell carcinoma. Molecular mechanisms altered in NSCLC include activation of oncogenes, such as K-RAS and c-erbB-2, and inactivation of tumorsuppressor genes, such as p53, p16INK4a, RAR-beta, and RASSF1. Point mutations within the K-RAS gene inactivate GTPase activity and the p21-RAS protein continuously transmits growth signals to the nucleus. Overexpression of c-erbB-2 or EGFR leads to a proliferative advantage. Inactivating mutation of p53 can lead to more rapid proliferation and reduced apoptosis. The protein encoded by the p16INK4a inhibits formation of CDK-cyclin-D complexes by competitive binding of CDK4 and CDK6. Loss of p16INK4a expression is a common feature of NSCLC. RAR-beta is a nuclear receptor that bears vitamin-A-dependent transcriptional activity. RASSF1A is able to form heterodimers with Nore-1, an RAS effector.Therefore loss of RASSF1A might shift the balance of RAS activity towards a growth-promoting effect. |
| No. of Genes in ADHDgene | 10 |
| Source | Pathway by Database Search |
Pathway related genes in ADHDgene (count: 10)
Literature-origin genes (count: 1)
| Approved Symbol | Approved Name | Location | No. of Studies (significant/non-significant/trend)  |
|---|---|---|---|
| FHIT | fragile histidine triad gene | 3p14.2 | 1(0/0/1) |
Genes from other sources (count: 9)
| Approved Symbol | Approved Name | Location | Source |
|---|---|---|---|
| PRKCB | protein kinase C, beta | 16p12 | Mapped by significant region |
| PIK3R1 | phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | 5q13.1 | Mapped by significant region |
| CCND1 | cyclin D1 | 11q13 | Mapped by significant region |
| BAD | BCL2-associated agonist of cell death | 11q13.1 | Mapped by significant region |
| PIK3CG | phosphoinositide-3-kinase, catalytic, gamma polypeptide | 7q22 | Mapped by CNV |
| MAPK3 | mitogen-activated protein kinase 3 | 16p11.2 | Mapped by CNV |
| MAPK1 | mitogen-activated protein kinase 1 | 22q11.2 | Mapped by LD-proxy |
| PLCG2 | phospholipase C, gamma 2 (phosphatidylinositol-specific) | 16q24.1 | Mapped by significant region |
| ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | 17q11.2-q12 | Mapped by LD-proxy |